View Post

Savvy Cooperative: Paid Opportunity for People Diagnosed with Breast Cancer, currently taking Ibrance or Verzenio

In Paid Opportunities For The Cancer Community by Barbara Jacoby

SCREENER Eligibility Criteria: Adult who has been diagnosed with breast cancer Currently taking Ibrance or Verzenio NOTE: Only patients with verified diagnoses will be considered US resident Details: 60-minute virtual interview From home Receive: $100 Link: https://gigs.savvy.coop/bcancer2/?r=44951 Why Sign Up? Your experiences are so valuable and important to creating better products and services, that companies and researchers will pay you …

View Post

Lilly reports positive PRO from high-risk early breast cancer trial

In Clinical Studies News by Barbara Jacoby

From: clinicaltrialsarena.com Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC).  Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The move comes after a primary outcome analysis …

View Post

Lilly’s Verzenio scores a win in early-stage breast cancer

In Clinical Studies News by Barbara Jacoby

Positive data was presented at 2020 ESMO virtual congress In the monarchE trial, patients with hormone receptor positive (HR+), HER2-negative high-risk early breast cancer were given Verzenio (abemaciclib) in combination with endocrine therapy. In addition to cutting the risk of cancer recurrence by 25%, 7.8% of the Verzenio treatment group had a relapse compared to 11.3% of patient in the …

View Post

CDK4/6 Inhibitors Shift Standards in HR+ Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Erica DiNapoli From: onclive.com Most discussion in hormone receptor (HR)–positive metastatic breast cancer are now focused on CDK4/6 inhibition, according to Denise A. Yardley, MD, who added that, after demonstrating significant survival benefits, these agents have transformed the standard of care. “There are 3 key agents: palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). Several phase 3 trials incorporating these …

View Post

CDK4/6 Inhibitors for Breast Cancer: Who Does, Doesn’t Benefit?

In Clinical Studies News by Barbara Jacoby

By: Nick Mulcahy From: medscape.com One of the success stories in recent years in the treatment of metastatic, hormone-receptor positive breast cancer has been the addition of drugs acting as inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) on top of endocrine therapy. Three such drugs are now available — palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib (Verzenio, Lilly). …

View Post

Lilly Receives Additional FDA Approval for Verzenio™ (abemaciclib), as Initial Treatment for Advanced Breast Cancer

In In The News by Barbara Jacoby

From: PR Newswire Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. This additional FDA approval …

View Post

Eli Lilly wins U.S. approval for breast cancer drug

In In The News by Barbara Jacoby

By: Bill Berkrot From: reuters.com The U.S. Food and Drug Administration said on Thursday it approved an Eli Lilly and Co drug to treat advanced breast cancer that has progressed following prior treatment. The drug, abemaciclib, which will be sold under the brand name Verzenio, will carry a list price before any discounts or rebates of about $10,948 per month, …